Compare CEPU & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | TWST |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2018 | 2018 |
| Metric | CEPU | TWST |
|---|---|---|
| Price | $17.23 | $42.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $17.50 | ★ $44.67 |
| AVG Volume (30 Days) | 271.8K | ★ 1.2M |
| Earning Date | 03-10-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $607,552,200.00 | $376,572,000.00 |
| Revenue This Year | $16.07 | $16.69 |
| Revenue Next Year | $15.36 | $15.08 |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.43 | $23.30 |
| 52 Week High | $18.50 | $55.33 |
| Indicator | CEPU | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 68.38 |
| Support Level | $14.77 | $39.13 |
| Resistance Level | $15.88 | $45.76 |
| Average True Range (ATR) | 0.85 | 2.34 |
| MACD | -0.01 | 0.51 |
| Stochastic Oscillator | 67.19 | 76.32 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.